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Abstract
Unilateral and bilateral subthalamic nucleus deep brain stimulation (STN DBS) in
Parkinson’s disease (PD) result in weight gain in the initial postoperative months,
but little is known about the changes in weight following unilateral and staged
bilateralSTNDBSoverlongertimeintervals.Acase–controlcomparisonevaluated
weight changes over 2 years in 43 consecutive unilateral STN DBS patients, among
whom 25 elected to undergo staged bilateral STN DBS, and 21 age-matched and
disease severity matched PD controls without DBS. Regression analyses incorpo-
rating age, gender, and baseline weight in case or control were conducted to assess
weight changes 2 years after the initial unilateral surgery. Unilateral STN DBS and
staged bilateral STN DBS patients gained 3.9± 2.0 kg and 5.6± 2.1 kg versus their
preoperative baseline weight (P < 0.001, respectively) while PD controls without
DBS lost 0.8 ± 1.1 kg. Although bilateral STN DBS patients gained 1.7 kg more
than unilateral STN DBS patients at 2 years, this difference was not statistically
signiﬁcant (P = 0.885). Although there was a trend toward greater weight gain in
staged bilateral STN DBS patients versus unilateral patients, we found no evidence
for an equivalent or synergistic increase in body weight following placement of the
second DBS electrode.
Introduction
Subthalamic nucleus deep brain stimulation (STN DBS) is
an effective treatment for motor symptoms in patients with
advanced Parkinson’s disease (PD) who no longer respond
optimally to medical therapy (Deuschl et al. 2006; Weaver
etal.2009).AlthoughmuchisknownabouttheeffectsofDBS
on motor function,less isknown aboutthe effectsof DBS on
nonmotorsymptoms.Stereotacticsurgicaltreatmentsforad-
vanced PD including STN and GPI (globus pallidus interna)
DBS and pallidotomy have been associated with postopera-
tive weight gain (Ondo et al. 2000; Sauleau et al. 2009). In
contrast, both early and advanced PD in the absence of DBS
are associated with weight loss (Chen et al. 2003; Uc et al.
2006; Bachmann and Trenkwalder, 2006). Various studies
have shown that bilateral STN stimulation results in postop-
erativeweightgainofapproximately10kgatoneyear(Macia
et al. 2004; Tuite et al. 2005; Novakova et al. 2007), 6 kg at
an average of 16 months (Bannier et al. 2009), and 4 kg at
ﬁve years postoperatively (Krack et al. 2003). Although uni-
lateral subthalamic stimulation results in weight gain as well,
comparisonacrossstudiessuggesttheamountofweightgain
is quantitatively less (4.3 kg) at 1 year follow up compared
to bilateral stimulation (Macia et al. 2004; Tuite et al. 2005;
Novakova et al. 2007; Walker et al. 2009a). Little is known
a b o u tc h a n g e si nw e i g h to v e rl o n g e rt i m ei n t e r v a l so rt h e
extent of additional weight gain following staged placement
ofasecondbrainstimulatorontheoppositesideofthebrain
(Bannier et al. 2009; Walker et al. 2009a). Our clinical prac-
tice is to place a unilateral DBS electrode contralateral to
the most affected hemibody, and then place another stimu-
lator in a staged procedure on the opposite side of the brain
when clinically needed. The goal of this study was to com-
pare weight changes in PD patients who underwent both
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unilateral and staged bilateral STN DBS over longer time
intervals (2 years) versus age-matched and disease severity
matched PD controls without DBS.
Methods
A retrospective case–control study evaluated the change in
weight over a 2-year time interval following unilateral and
staged bilateral STN DBS in PD. The Institutional Review
BoardattheUniversityofAlabamaatBirminghamapproved
thestudy.Writtenconsentwasnotobtainedindividuallyfrom
patients because the data were acquired retrospectively and
deidentiﬁed. All patients were diagnosed with idiopathic PD
by a movement disorder specialist using UK Brain Bank cri-
teria (Daniel and Lees, 1993). Data on weight were reviewed
from43consecutivepatientswithmoderate-to-advancedPD
who underwent unilateral STN DBS contralateral to their
most affected hemibody. Improvements in motor function
in following unilateral STN DBS in this cohort of patients at
1 year postoperatively are described in a prior study (Walker
et al. 2009b). Among these patients, 25 subsequently un-
derwent staged bilateral STN DBS when clinically necessary
within 2 years of their ﬁrst electrode placement. These 25
patients who had the staged procedure on the opposite side
of the brain within 2 years of their initial surgery are referred
to as “staged bilateral STN” patients throughout. Patients
who did not undergo the staged bilateral procedure within 2
yearsoftheirinitialsurgeryarereferredtoas“unilateralSTN”
patients,regardlessofwhethertheyhavesubsequentlyunder-
gonethestagedbilateralprocedureafterthe2-yearfollow-up
period.
Weights were recorded at baseline and at 3, 6, 12, and
24 months following surgery. A second baseline weight was
determined for patients who received staged placement of
contralateral STN DBS, deﬁned as the weight immediately
prior to their second surgery. The staged bilateral STN DBS
patients had a minimum of 3 months of subsequent follow
up to evaluate weight change. Nine patients whose weight
data were not available or incomplete were excluded. The
initial age for the determination of baseline weight in the
DBS patients was deﬁned as the age of the subject on the day
of STN DBS placement. All weights were measured during
routine clinic appointments on the same electronic scale.
PD controls without DBS were identiﬁed in the University
of Alabama at Birmingham Movement Disorders Registry,
group matching to achieve similar age, gender, and disease
severity using duration of disease and levodopa-equivalent
dose (LED) per day. All controls were diagnosed and fol-
lowed by a movement disorders neurologist at University of
Alabama. Controls were treated with levodopa and had at
least 24 months of routine clinical follow-up to establish a
change in weight over time.
The LED was calculated by estimating that a 100 mg daily
dose of levodopa was equivalent to the following doses of
other medications: 133 mg of controlled-release levodopa,
75 mg of levodopa plus entacapone, 1 mg of pramipexole,
5 mg of ropinirole, and 10 mg of apomorphine (Deuschl
etal.2006).Controlswithmajormedicalcomorbiditiesother
thanPDsuchascancerorothersimilarchronicdiseaseswere
excluded.Thebaselineweightforthecontrolswastheweight
on the chart 2 years prior to the most recent clinic visit.
Descriptive statistics (means, variance, proportions) were
computed on both cases and controls. All data are reported
as mean ± standard error of the mean. Regression analyses
incorporating age, gender, baseline weight, body mass index
(BMI), and case or control were conducted to assess the ﬁ-
nal weight and weight change using SAS PROC GLM (SAS
version 9. 1. 3). Chi-square statistics were used to estimate
the proportion of patients who gained weight over the time
period, with net weight gain and weight loss deﬁned as any
increase or decrease in body weight over the study period.
Categorical analyses of change in body mass index (BMI) by
National Heart Lung and Blood Institute (NHLBI) criteria
(underweight ≤ 18.5, normal weight 18.5–24.9, overweight
and obese ≥ 25) were conducted using chi-square statistics
(National Heart, Lung, and Blood Institute, 2000). The Uni-
ﬁedParkinson’sDiseaseRatingScale(UPDRS)wasmeasured
“off” and “on” medication in DBS patients at speciﬁed in-
tervals, but not in PD controls without DBS (Langston et al.
1992).
Results
In this study, 43 consecutive patients with moderate-to-
advanced PD underwent successful unilateral STN DBS con-
tralateral to their most affected hemibody, and 25 (58%) of
these patients underwent staged bilateral STN DBS within 2
years of their ﬁrst electrode placement. The average age and
duration of disease of the DBS patients were 60.6 ± 1.5 and
14.1± 0.90 years, respectively, and the average age and dura-
tion of disease of the PD controls without DBS were 59.7 ±
1.7 and 11.4 ± 0.97 years, respectively. Among all of the pa-
tients, 73% were male. The average latency between initial
and staged electrode placement was 12.5 ± 1.6 months for
patientswhoelectedtohavestagedbilateralSTNDBSwithin
the 2-year interval.
Weight gain was statistically signiﬁcant in both the uni-
lateral and staged bilateral STN DBS patients at 2 years
postoperatively versus controls who did not undergo DBS
(P <0.001,respectively).UnilateralSTNDBSpatientsgained
3.9 ± 2.0 kg and staged bilateral STN DBS patients gained
5.6 ± 2.1 kg, while controls lost 0.8 ± 1.1 kg over the 2-year
period (mean ± standard error, Fig. 1). Although the mean
weight gain following staged bilateral STN DBS was 1.7 kg
greaterthanthatintheunilateralDBSpatientsat2years,this
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Figure 1. (A) Weight gain (mean ± SEM) for both unilateral and bilateral STN DBS patients is statistically signiﬁcant at 24 months when compared
with PD controls without DBS. A smaller weight gain occurred in the staged bilateral DBS patients following placement of the second stimulator but
this difference was not statistically signiﬁcant. (B) Histogram showing signiﬁcant weight gain in both unilateral and staged bilateral DBS patientsa t
24 months (*P < 0.001 and P < 0.001, respectively). The patients who underwent staged bilateral DBS within 24 months of their initial electrode
placement weighed signiﬁcantly less than controls or unilateral patients preoperatively (#P < 0.0001).
difference was not statistically signiﬁcant (P = 0.885). The
staged bilateral STN DBS patients did gain a mean of 1.4 ±
0.8 kg at 1 year after the second staged surgery versus their
weight immediately prior to the second electrode placement
(Fig. 1), although this change was not statistically signiﬁcant
(P = 0.119). A power calculation suggests that 87 additional
DBS subjects would be required to show a signiﬁcant weight
gainatanaveragefollow-upof1yearafterthestagedbilateral
surgery,supportingatrendformodestadditionalweightgain
following staged placement of a second STN DBS electrode.
The majority of the weight gain in the STN DBS patients
occurred in the ﬁrst six months after the initial electrode
placement in both the unilateral STN DBS patients and the
staged bilateral STN DBS patients. There was a trend to-
ward weight loss in the unilateral patients while weight gain
persisted in the staged bilateral patients over the 1- to 2-
yearpostoperativeinterval.Themaximumamountofweight
gainedbyaunilateralSTNDBScaseat2yearspostoperatively
was 20.5 kg, and a greater than 10 kg weight gain occurred
in three unilateral cases (20%). The maximum amount of
weight gained by a staged bilateral STN DBS case at 2 years
postoperativelywas20kg,andgreaterthan10kgweightgain
occurred in four staged bilateral cases (25%). Weight gain
of 10 kg or greater did not occur in any of the controls at
2 years, while weight loss occurred over a 2-year interval in
50% of the controls versus only 25% and 18% of the uni-
lateral and staged bilateral STN DBS patients (P < 0.001,
respectively,unilateralandstagedbilateralSTNDBSpatients
vs. controls, Table 1). Quantitative changes in weight were
similar between men and women in the DBS and control
groups. Male cases gained an average of 5.07± 1.65 kg com-
p a r e dt om a l ec o n t r o l sw h ol o s t0 . 8 8± 1.10 kg. Female cases
gained an average of 4.04 ± 3.06 kg compared to a loss of
-0.38±2.79kgforfemalecontrols.Therewerenosigniﬁcant
differences in weight change between the cases and controls
by gender (males gained 5.95 kg more between cases and
controls compared to 4.42 kg for females). Additionally, no
signiﬁcant relationship was noted between the initial side for
STN DBS surgery and weight gain.
Interestingly, we found that the patients who underwent
stagedbilateralsurgerywithin2yearsoftheirinitialelectrode
placement weighed an average of 10.2 kg (22.4 lbs.) less at
baseline than both the patients who remained unilateral at
2 years and the PD controls without DBS (P < 0.0001 and
P < 0.0001, respectively). Indeed, two patients (9%) among
the staged bilateral STN DBS group were underweight by
the NHLBI BMI criteria preoperatively versus none of the
unilateral STN DBS patients or the controls without DBS.
The staged bilateral STN DBS patients had a slightly longer
duration of disease than the unilateral patients, and their
preoperative motor function was slightly worse based on the
UPDRSpart3“off”(P =0.0308).Onlyatrendtowardgreater
preoperative disability was present in the UPDRS total score
(P = 0.0982).
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Table 1.
Pv a l u e Pv a l u e
Unilateral Bilateral unilateral staged bilateral
STN DBS STN DBS PD controls vs. controls vs. controls
Number of patients 18 25 21 – –
Age ± SD 60 ± 2.5 61.1 ± 1.1 59.7 ± 1.7 0.4605 0.2447
Gender proportion (M/F) 13/18 (72%) 17/25 (68%) 17/21 (81%) 0.2053 0.2229
Duration of disease (years) 10.3 ± 0.92 12.7 ±1.4 11.4 ± 0.97 0.2053 0.2229
Levodopa equivalent dose at baseline (mg/day) 1245 ± 114 1233 ± 67 1233 ± 62 0.9085 0.3712
Weight at 0 months (kg) 85.4 ± 5.5 74.5 ± 4.5 84.3 ± 3.7 0.6024 <0.0001
Proportion losing weight over 24 months 26% 18% 50% <0.0001 <0.0001
There were no remarkable correlations between preoper-
ative tremor subscore, asymmetry index, or dyskinesia sub-
score and change in weight. Furthermore, there was no sig-
niﬁcant correlation between change in the UPDRS Part 3 in
the “practically deﬁned off” state (Langston et al. 1992) and
the change in weight in the DBS patients. Importantly, UP-
DRS Part 3 “off” medication ratings were not available for
the controls without DBS, therefore it was not possible to
correlate changes in the UPDRS “off” and weight over time
in patients with and without the DBS intervention.
Discussion
Our clinical practice is to initially place a DBS electrode in
theSTNcontralateraltothemostseverelyaffectedsideofthe
bodyandthenplaceasecondstimulatorintheoppositeSTN
inastagedfashionwhenclinicallyneeded.At2yearspostop-
eratively,PDpatientswithbothunilateralandstagedbilateral
STN DBS show sustained weight gain, and the weight of the
PD controls without DBS trend downwards over the same
time interval. Although the mean weight gain was greater
in patients who underwent staged bilateral STN DBS over
2 years versus those who remained unilateral over 2 years,
the difference in weight gain between the groups was modest
and not statistically signiﬁcant. We therefore found no ev-
idence for an equivalent amount of additional weight gain
or a synergistic effect of the second subthalamic stimulator
on body weight. These data may be useful for patients eval-
uating the potential risks and beneﬁts of both unilateral and
stagedbilateralSTNDBSsurgeryforadvancedPD.Ourﬁnd-
ingssuggestthatalthoughweightgainlikelyoccursfollowing
the second surgery, it is more modest than the weight gain
following the ﬁrst surgery, assuming that the ﬁrst surgery is
performed contralateral to the more severely affected hemi-
body. Furthermore, the total weight gain in patients who
underwent bilateral STN DBS in this study is substantially
less (approximately 5 kg) than that reported in other studies
in which stimulators were placed bilaterally in a single pro-
cedure (approximately 10 kg) (Macia et al. 2004; Tuite et al.
2005; Novakova et al. 2007), suggesting a potential differen-
tial effect of initial bilateral STN DBS versus staged bilateral
DBS on weight gain. The magnitude of the observed changes
in body weight in patients undergoing staged bilateral STN
DBS surgery parallels ﬁndings from studies of motor func-
tion, suggesting that like weight gain, motor improvement
following staged placement of a second DBS electrode may
not be as large as that following the unilateral procedure
(Samii et al. 2007).
Unexpectedly, staged bilateral STN DBS patients weighed
an average of 10.9 kg less at baseline than both patients who
remainedunilateralfor2yearsandthecontrols.Indeed,9%of
the staged bilateral DBS group was found to be clinically un-
derweight by the NHLBI criteria preoperatively versus none
of the unilateral DBS patients or the controls (Fig. 2). Ad-
ditionally, subjects who underwent staged bilateral surgery
within 2 years of their original surgery had an average du-
ration of disease of 2 years longer than the unilateral STN
DBS patients prior to surgery. These ﬁndings suggest that
simplemeasuressuchasbodyweightanddurationofdisease
may capture aspects of PD disability that are not as clearly
reﬂected in clinical rating scales. Coupling our ﬁndings with
other studies in patients with PD, these data are consistent
with progressive weight loss over time in PD patients follow-
ing diagnosis (Chen et al. 2003).
A strength of this study is that a relatively large number
of DBS patients and controls without DBS were followed for
2 years after placement of the initial STN electrode. Addi-
tionally, within-subject comparisons of weight over time di-
minished intersubject variance. A potential limitation of this
study is that the participants were not randomized to uni-
lateral DBS, staged bilateral DBS, or medical therapy alone,
and the decision to undergo staged bilateral procedure was
driven by clinical necessity. Although these considerations
might introduce bias into the results because of underlying
differences in PD phenotype, disease severity, or other fac-
tors, we attempted to minimize such potential confounds
by controlling for disease severity, duration of disease, dose
of dopaminergic medications, age, and gender. Regardless,
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Figure 2. Distribution of body mass index (BMI) at the time of surgery (baseline) and at 24 months postoperatively. Patients who underwent staged
STN DBS within the 24-month period were more likely to be clinically underweight by NHLBI BMI criteria.
our ﬁndings are reported from DBS patients in real-world
movement disorders practice, which could increase the gen-
eralizability of our results to other clinical settings.
The mechanisms underlying changes in weight in PD pa-
tients with and without DBS have been a matter of debate.
In PD patients without DBS, weight loss may result from in-
creasedenergyexpenditurefrommotorsymptoms,decreased
caloric intake because of motor disability, and/or changes in
central appetite mechanisms from medications or from PD
itself (Montaurier et al. 2007). Although the mechanism for
weight gain following STN DBS is also likely multifactorial,
several studies argue for reduction of motor symptoms play-
ing a signiﬁcant role in postoperative weight gain. Rigidity,
tremor, and bradykinesia associated with PD are relieved
within seconds to minutes following activation of STN DBS
at therapeutic settings (Moro et al. 2002). Calorimetric stud-
ies show similar temporal dynamics, with bilateral STN DBS
decreasing the basal energy expenditure within minutes af-
ter starting therapeutic stimulation (Montaurier et al. 2007).
Despitethis,weightgainhasnotbeenconsistentlycorrelated
withmotorbeneﬁtfromDBSsurgeryinpriorstudies(Macia
et al. 2004; Barichella et al. 2003; Walker et al. 2009b) but
see (Montaurier et al. 2007; Bannier et al. 2009). A potential
confound of these studies is that they are relatively small and
lack a control group without the DBS intervention. An asso-
ciation between change in weight and change in the UPDRS
“off”medicationsmaythereforebeelusive,asthemajorityof
the DBS patients sustain both improvement in motor func-
tion and weight gain. If a study were to evaluate changes in
motorfunction“off”medicationsandweightinpatientswith
and without DBS, it would be reasonable to expect worsen-
ing of the UPDRS “off” and relative weight loss in patients
without DBS and improvements in the UPDRS “off” and
weight gain in patients with DBS, increasing the likelihood
of a correlation between improvement in motor function
and weight gain. Another hypothesis regarding the observed
weight changes is that a component of the weight gain may
result from alteration of central appetite mechanisms via di-
rect or indirect stimulation of the hypothalamic region. For
instance, disruption of the melanocortin system associated
with DBS therapy has been implicated in weight changes in
patientswithPD(Escamilla–Sevillaetal.2011).Althoughour
data cannot directly address this issue, weight gain has been
describedfollowingbothpallidotomyandglobuspallidusin-
terna (GPi) DBS, a site more anatomically remote from the
satiety center (Ondo et al. 2000; Sauleau et al. 2009). There
aremixedﬁndingscomparingweightchangesfollowingSTN
and GPi DBS, with some authors reporting greater weight
gain following STN DBS and a more recent study ﬁnding
no signiﬁcant difference in weight change between the two
targets (Sauleau et al. 2009; Locke et al. 2011). As suggested
previously, other factors such as changes in dopaminergic
medicationsmayalso playa role inweightchangesafterDBS
surgery.
Regardless of whether STN DBS results in greater weight
gain than what would be expected from normalizing energy
expenditure from motor symptoms, the possibility has been
raised that STN DBS increases cardiovascular risk and other
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adverse health related effects of being overweight (Bannier
et al. 2009). Our data provide evidence that patients who
underwentstagedbilateralsurgerywithin2yearsoftheirini-
tial surgery had longer disease duration and were more likely
to be clinically underweight preoperatively by NHLBI BMI
criteria. Additionally, the unilateral STN DBS patients began
to show a trend toward resumption of weight loss at 2 years
postoperatively (Fig. 1), which agrees with pooled data from
multiple studies suggesting that the initial amount of weight
gain following STN DBS may not necessarily be sustained
over the years following surgery (Krack et al. 2003; Macia
et al. 2004; Montaurier et al. 2007; Novakova et al. 2007).
Moststudiesassociatingcardiovascularriskandobesityhave
evaluated chronic obesity rather than more subacute weight
gain. While excessive postoperative weight gain is undesir-
able and may present health risks in some patients, further
studies should ascertain to what degree weight gain associ-
ated with DBS is sustained and how it impacts health. The
results of such efforts have the potential to shift the beneﬁt
versus risk assessment for patients in whom this treatment
may dramatically impact quality of life.
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